Notably, Rencuzogullari O. and colleagues reported that in pancreatic cancer, palbociclib treatment also acts through the upregulation of this metabolic miRNA, regulating AMPK/mTOR signaling and enhancing pancreatic cancer cell death [85]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.